PharmAthene

PharmAthene, Altimmune merge

Friday, January 20, 2017

PharmAthene and Altimmune, a privately-held immunotherapeutics company targeting infectious diseases, announced the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Altimmune’s current investors include Novartis Venture Fund, HealthCap, Truffle Capital and Redmont Capital. The combined company will be a fully-integrated and diversified immunotherapeutics company with four clinical stage and one preclinical stage programs. The proposed transaction does not affect PharmAthene’s previously announced special one-time cash dividend of $2.91 per share of common stock.

[Read More]

PharmAthene to cut two-thirds of staff

Wednesday, March 11, 2015

Annapolis, Md.-based PharmAthene will launch a realignment plan that includes reducing its staffing levels by approximately two-thirds. Eric Richman, president and CEO, will remain a member of the board of directors but will no longer serve as an officer of the company, effective March 11. He will continue to play a key role in managing the ongoing litigation, other legal matters and strategic transactions in his role as director.

[Read More]

PharmAthene awarded $28.1M to develop thermostable anthrax vaccine

Thursday, September 11, 2014

PharmAthene, an Annapolis, Md.-based biodefense company developing medical countermeasures against biological and chemical threats, has announced the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has awarded the company a contract, valued at up to $28.1 million if all contract options are exercised, for the development of a next-generation anthrax vaccine based on the company’s proprietary rPA anthrax vaccine technology platform.

[Read More]

FDA lifts clinical hold on anthrax vaccine program

Thursday, May 30, 2013

PharmAthene, a biodefense company developing medical countermeasures against biological and chemical threats, said the FDA has lifted the clinical hold previously placed on a proposed phase II study of SparVax, a next generation recombinant anthrax vaccine.

“Anthrax has been identified as one of the foremost potential biological threats to the nation,” said Eric I. Richman, president and CEO.  “The U.S. government’s requirement for a recombinant anthrax vaccine for the civilian Strategic National Stockpile is an important national security imperative that remains unfilled. Next-generation anthrax vaccines like SparVax, which employ modern vaccine technology, offer the potential for improved convenience, cost-effectiveness, more rapid immunity, and the ability for large scale rapid delivery.”

[Read More]